FDA approves prostate cancer vaccine from Seattle company

FDA approves prostate cancer vaccine from Seattle company
The Food and Drug Administration says it has approved a drug by a Seattle biotech company that is designed to stimulate a patient’s immune system to fight prostate cancer.

Read more on KING5 Seattle

Novel Therapeutics from Modern Biotechnology: From Laboratory to Human Testing

Product Description
This volume addresses the particular problems associated with several classes of biotechnology products, and at the same time demonstrates that the principles are the same as in the development of small new chemical entities. The first chapter addresses FDA regulatory expectations for biotech products. The next several chapters discuss general issues common to each class of biotech drug such as proteins, peptides, and nucleic acids. The balance of the chapters deal with specific biotech drugs that have successfully made it into clinical trials. The reviews are written by renowned experts in their fields.

Novel Therapeutics from Modern Biotechnology: From Laboratory to Human Testing

BioBytes: What are biosimilars?

Biosimilars, also known as follow-on biologics, may eventually expand access and provide patients a more affordable alternative to innovative, lifesaving medicines. However, there are a few important safeguards that must be put into place before these similar but not the same versions of biologics can be safely introduced to the public. Join Dr. Targan as he explains the complex nature of biologics and the steps that need to be taken by Congress and the FDA to ensure that biosimilars are safe and effective while ensuring the continued development of cutting-edge medicines.

FDA approves country’s first cancer-treatment vaccine

FDA approves country’s first cancer-treatment vaccine
An 18-year roller-coaster ride for Seattle biotech Dendreon ended on a high point Thursday, with federal approval of the country’s first cancer-treatment vaccine.

Read more on Seattle Times

Dendreon Hits The Jackpot

Dendreon Hits The Jackpot
The FDA approval of Provenge leads to a huge spike for biotech firm.

Read more on Forbes

« Previous Page — Next Page »